DK1849470T3 - Anticancerlægemiddel indeholdende alpha, alpha, alpha-trifluorthymidin og thymidinphosphorylaseinhibitor - Google Patents
Anticancerlægemiddel indeholdende alpha, alpha, alpha-trifluorthymidin og thymidinphosphorylaseinhibitor Download PDFInfo
- Publication number
- DK1849470T3 DK1849470T3 DK06712292.9T DK06712292T DK1849470T3 DK 1849470 T3 DK1849470 T3 DK 1849470T3 DK 06712292 T DK06712292 T DK 06712292T DK 1849470 T3 DK1849470 T3 DK 1849470T3
- Authority
- DK
- Denmark
- Prior art keywords
- cancer
- drug
- dose
- day
- ftd
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (5)
1. Mosteller-formlen fif. N. Enal. J. Med. 1987 Oct 22; 317 (17): 1098 (letter))
1. Terapeutisk cancerlægemiddel, som er en sammensætning omfattende α,α,α-trifluorthymidin (FTD) og 5-chlor-6-(1-(2-iminopyrrolidinyl)methyl)uracil-hydrochlorid i et molforhold på 1 : 0,5, til anvendelse ved behandling af cancer hos en patient, der er et menneske, med behov herfor ved oral indgivelse af lægemidlet i en dosis, som en dosis af FTD, på 20 til 80 mg/m2/dag, to gange dagligt.
2. DuBois og DuBois-formlen (jf. Arch. Int. Med. 1916 17: 863-71; J. Clin. Anesth. 1992; 4 (1): 4-10) (a) legemsoverflade (m2)= 0,20247 x højde (m)0,725 x vægt (kg)0 425 (b) legemsoverflade (m2)= 0,007184 x højde (cm)0,725 x vægt (kg)0,425
2. Terapeutisk cancerlægemiddel til anvendelse ifølge krav 1, hvor lægemidlet indgives oralt til en patient med behov herfor i en dosis, som en dosis af FTD, på 25 til 75 mg/m2/dag, indgivet to gange dagligt.
3. Haycock-formlen (jf. The Journal of Pediatrics 1978 93: 1: 62-66)
3. Terapeutisk cancerlægemiddel til anvendelse ifølge krav 1, hvor lægemidlet indgives to gange dagligt i henhold til en ugebaseret plan, der indbefatter indgivelse i fem dage og to dages pause.
4. Gehan and George-formlen (jf. Cancer Chemother. Rep. 1970 54: 225-35)
4. Terapeutisk cancerlægemiddel til anvendelse ifølge krav 1, hvor lægemidlet indgives på en sådan måde, at en ugentlig doseringscyklus bestående af indgivelse i fem dage og to dages pause udføres i to uger, efterfulgt af pause i to uger.
5. Terapeutisk cancerlægemiddel til anvendelse ifølge krav 1, hvor lægemidlet indgives til en patient med behov herfor i en dosis, som en dosis af FTD, på FTD, på 50 til 70 mg/m2/dag.
6. Terapeutisk cancerlægemiddel til anvendelse ifølge krav 1 til 5, hvor lægemidlet indgives til en patient med behov herfor i en dosis, som en dosis af FTD, på 70 mg/m2/dag.
7. Terapeutisk cancerlægemiddel til anvendelse ifølge et hvilket som helst af kravene 1 til 6, hvor den cancer, som det terapeutiske cancerlægemiddel anvendes mod, indbefatter øsofaguxcancer, gastrisk cancer, levercancer, galdeblære-/galdevejscancer, pancreascancer, kolorektal cancer, hoved- og halscancer, lungecancer, brystcancer, cervixcancer, ovariecancer, blærecancer, prostatacancer, testikeltumor, bløddels- og knoglesarkom, hudcancer, malignt lymfom, leukæmi og hjernetumor.
8. Terapeutisk cancerlægemiddel til anvendelse ifølge et hvilket som helst af kravene 1 til 7, hvor den cancer, som det terapeutiske cancerlægemiddel anvendes mod, indbefatter maligne solide cancere udvalgt blandt gastrisk cancer, pancreascancer, brystcancer, kolorektal cancer, hoved- og halscancer, galdeblære-/galdevejscancer og lungecancer.
9. Terapeutisk cancerlægemiddel til anvendelse ifølge et hvilket som helst af kravene 1 til 8, hvor dosen af sammensætningen, der indgives til en patient med behov herfor, bestemmes på basis af patientens legemsoverflade, hvilken legemsoverflade beregnes ved anvendelse af en hvilken som helst af de følgende beregningsformler 1 til 5:
5. Bovd-formlen (if. Minneaoolis: Universitv of Minnesota Press. 19351
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/042,059 US7799783B2 (en) | 2005-01-26 | 2005-01-26 | Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor |
| JP2005165156 | 2005-06-06 | ||
| PCT/JP2006/301097 WO2006080327A1 (ja) | 2005-01-26 | 2006-01-25 | α，α，α－トリフルオロチミジンとチミジンホスホリラーゼ阻害剤とを配合した抗癌剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DK1849470T3 true DK1849470T3 (da) | 2017-08-14 |
| DK1849470T4 DK1849470T4 (en) | 2024-04-02 |
Family
ID=36740357
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK06712292.9T DK1849470T4 (en) | 2005-01-26 | 2006-01-25 | Cancerlægemiddel, som indeholder alpha, alpha, alpha-trifluorthymidin og thymidin-phosphorylase-inhibitor |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP1849470B2 (da) |
| JP (1) | JP5576591B2 (da) |
| KR (1) | KR101468216B1 (da) |
| AU (1) | AU2006209547C1 (da) |
| BE (1) | BE2017C028I2 (da) |
| CA (1) | CA2594713A1 (da) |
| CY (2) | CY2017029I2 (da) |
| DK (1) | DK1849470T4 (da) |
| ES (1) | ES2630002T5 (da) |
| FI (1) | FI1849470T4 (da) |
| FR (1) | FR17C1028I2 (da) |
| HU (2) | HUE033306T2 (da) |
| LT (2) | LT1849470T (da) |
| LU (1) | LUC00036I2 (da) |
| NL (1) | NL300889I2 (da) |
| PL (1) | PL1849470T5 (da) |
| PT (1) | PT1849470T (da) |
| SI (1) | SI1849470T2 (da) |
| TW (1) | TWI362265B (da) |
| WO (1) | WO2006080327A1 (da) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7776314B2 (en) | 2002-06-17 | 2010-08-17 | Grunenthal Gmbh | Abuse-proofed dosage system |
| US20070048228A1 (en) | 2003-08-06 | 2007-03-01 | Elisabeth Arkenau-Maric | Abuse-proofed dosage form |
| DE10336400A1 (de) | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
| DE10361596A1 (de) | 2003-12-24 | 2005-09-29 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
| DE102005005446A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Bruchfeste Darreichungsformen mit retardierter Freisetzung |
| DE102004032049A1 (de) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Gegen Missbrauch gesicherte, orale Darreichungsform |
| JP5576591B2 (ja) | 2005-01-26 | 2014-08-20 | 大鵬薬品工業株式会社 | α，α，α−トリフルオロチミジンとチミジンホスホリラーゼ阻害剤とを配合した抗癌剤 |
| DE102005005449A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
| DE102007011485A1 (de) | 2007-03-07 | 2008-09-11 | Grünenthal GmbH | Darreichungsform mit erschwertem Missbrauch |
| US8536188B2 (en) * | 2007-04-25 | 2013-09-17 | Cyclacel Limited | Dosing regimens for treatment of proliferative disorders comprising administration of sapacitabine |
| CA2713128C (en) | 2008-01-25 | 2016-04-05 | Gruenenthal Gmbh | Pharmaceutical dosage form |
| AU2009243681B2 (en) | 2008-05-09 | 2013-12-19 | Grunenthal Gmbh | Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step |
| JP2011520845A (ja) * | 2008-05-15 | 2011-07-21 | カソリック ユニヴェルシテイト ルーヴェン，ケー．ユー． ルーヴェン アール アンド ディー | 抗癌剤の組合せによる治療 |
| KR101738369B1 (ko) | 2009-07-22 | 2017-05-22 | 그뤼넨탈 게엠베하 | 핫 멜트 압출된 제어 방출 투여형 |
| CN102639118B (zh) | 2009-07-22 | 2015-07-29 | 格吕伦塔尔有限公司 | 氧化稳定的抗干扰剂型 |
| BR112013005194A2 (pt) | 2010-09-02 | 2016-05-03 | Gruenenthal Gmbh | forma de dosagem resistente à violação compreendendo sal inorgânico |
| TWI516286B (zh) | 2010-09-02 | 2016-01-11 | 歌林達股份有限公司 | 含陰離子聚合物之抗破碎劑型 |
| EA201400172A1 (ru) | 2011-07-29 | 2014-06-30 | Грюненталь Гмбх | Устойчивая к разрушению таблетка, которая обеспечивает немедленное высвобождение лекарственного средства |
| BR112014001091A2 (pt) | 2011-07-29 | 2017-02-14 | Gruenenthal Gmbh | comprimido resistente à adulteração que fornece liberação imediata do fármaco |
| US9371380B2 (en) | 2011-08-16 | 2016-06-21 | Taiho Pharmaceutical Co., Ltd. | Antitumor agent and therapeutic effect prediction method for patients with KRAS-mutated colorectal cancer |
| TWI503122B (zh) * | 2012-02-15 | 2015-10-11 | Taiho Pharmaceutical Co Ltd | Oral administration of pharmaceutical compositions |
| TWI526210B (zh) * | 2012-02-15 | 2016-03-21 | Taiho Pharmaceutical Co Ltd | Oral pharmaceutical composition |
| MX356421B (es) | 2012-02-28 | 2018-05-29 | Gruenenthal Gmbh | Forma de dosificacion resistente a la manipulacion indebida que comprende un compuesto farmacologicamente activo y un polimero anionico. |
| EP2838512B1 (en) | 2012-04-18 | 2018-08-22 | Grünenthal GmbH | Tamper resistant and dose-dumping resistant pharmaceutical dosage form |
| US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
| WO2013173283A1 (en) | 2012-05-16 | 2013-11-21 | Novartis Ag | Dosage regimen for a pi-3 kinase inhibitor |
| JP6002835B2 (ja) * | 2013-03-27 | 2016-10-05 | 大鵬薬品工業株式会社 | 低用量イリノテカン塩酸塩水和物を含有する抗腫瘍剤 |
| KR101847252B1 (ko) * | 2013-03-27 | 2018-04-09 | 다이호야쿠힌고교 가부시키가이샤 | 이리노테칸염산염 수화물을 함유하는 항종양제 |
| AU2014266278B2 (en) * | 2013-05-17 | 2017-07-13 | Taiho Pharmaceutical Co., Ltd. | Therapeutic effect prediction method for colorectal cancer patient in whom expression of TK1 protein has increased |
| EP3003279A1 (en) | 2013-05-29 | 2016-04-13 | Grünenthal GmbH | Tamper-resistant dosage form containing one or more particles |
| US9737490B2 (en) | 2013-05-29 | 2017-08-22 | Grünenthal GmbH | Tamper resistant dosage form with bimodal release profile |
| BR112016000194A8 (pt) | 2013-07-12 | 2019-12-31 | Gruenenthal Gmbh | forma de dosagem resistente à violação contendo o polímero de acetato de etileno-vinila |
| HRP20230523T1 (hr) | 2013-09-06 | 2023-08-04 | Taiho Pharmaceutical Co., Ltd. | Antitumorski agens i sredstvo za poboljšavanje antitumorskog efekta |
| EP3073994A1 (en) | 2013-11-26 | 2016-10-05 | Grünenthal GmbH | Preparation of a powdery pharmaceutical composition by means of cryo-milling |
| WO2015173195A1 (en) | 2014-05-12 | 2015-11-19 | Grünenthal GmbH | Tamper resistant immediate release capsule formulation comprising tapentadol |
| EA201692388A1 (ru) | 2014-05-26 | 2017-05-31 | Грюненталь Гмбх | Лекарственная форма в виде множества частиц, защищенная от вызываемого этанолом сброса дозы |
| WO2016170097A1 (en) | 2015-04-24 | 2016-10-27 | Grünenthal GmbH | Tamper-resistant dosage form with immediate release and resistance against solvent extraction |
| JP2018526414A (ja) | 2015-09-10 | 2018-09-13 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 乱用抑止性の即放性製剤を用いた経口過剰摂取に対する保護 |
| WO2017119484A1 (ja) * | 2016-01-08 | 2017-07-13 | 大鵬薬品工業株式会社 | 免疫調節剤を含有する抗腫瘍剤及び抗腫瘍効果増強剤 |
| MA43977A (fr) | 2016-02-05 | 2018-12-12 | Taiho Pharmaceutical Co Ltd | Méthode de traitement de patients atteints de cancer souffrant d'insuffisance rénale grave |
| EP3730935A4 (en) | 2017-12-22 | 2022-02-23 | Taiho Pharmaceutical Co., Ltd. | METHOD OF DETECTING ANALOGUES OF TRIFLURIDIN AND/OR TIPIRACIL |
| US10866219B2 (en) | 2017-12-22 | 2020-12-15 | Taiho Pharmaceutical Co., Ltd. | Method for detecting trifluridine- and/or tipiracil-related substance |
| WO2019135405A1 (ja) | 2018-01-05 | 2019-07-11 | 大鵬薬品工業株式会社 | トリフルリジン由来の類縁物質の検出方法 |
| US10816517B2 (en) | 2018-01-05 | 2020-10-27 | Taiho Pharmaceutical Co., Ltd. | Method for detecting trifluridine-related substance by high-performance liquid chromatography |
| WO2026019875A1 (en) * | 2024-07-17 | 2026-01-22 | Jnd Therapeutics, Inc. | Methods and formulations for treatment of liver cancer using trifluridine |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100424934B1 (ko) * | 1995-03-29 | 2004-07-27 | 다이호야쿠힌고교 가부시키가이샤 | 우라실유도체및이를함유하는항종양효과증강제및항종양제 |
| AU699728B2 (en) * | 1996-09-24 | 1998-12-10 | Taiho Pharmaceutical Co., Ltd. | Cancerous metastasis inhibitors containing uracil derivatives |
| JP5576591B2 (ja) | 2005-01-26 | 2014-08-20 | 大鵬薬品工業株式会社 | α，α，α−トリフルオロチミジンとチミジンホスホリラーゼ阻害剤とを配合した抗癌剤 |
-
2006
- 2006-01-25 JP JP2007500529A patent/JP5576591B2/ja not_active Expired - Lifetime
- 2006-01-25 WO PCT/JP2006/301097 patent/WO2006080327A1/ja not_active Ceased
- 2006-01-25 ES ES06712292T patent/ES2630002T5/es not_active Expired - Lifetime
- 2006-01-25 HU HUE06712292A patent/HUE033306T2/hu unknown
- 2006-01-25 LT LTEP06712292.9T patent/LT1849470T/lt unknown
- 2006-01-25 DK DK06712292.9T patent/DK1849470T4/da active
- 2006-01-25 EP EP06712292.9A patent/EP1849470B2/en not_active Expired - Lifetime
- 2006-01-25 SI SI200632192T patent/SI1849470T2/sl unknown
- 2006-01-25 PT PT67122929T patent/PT1849470T/pt unknown
- 2006-01-25 AU AU2006209547A patent/AU2006209547C1/en not_active Expired
- 2006-01-25 PL PL06712292.9T patent/PL1849470T5/pl unknown
- 2006-01-25 CA CA002594713A patent/CA2594713A1/en not_active Withdrawn
- 2006-01-26 TW TW095103114A patent/TWI362265B/zh active
-
2007
- 2007-07-19 KR KR1020077016492A patent/KR101468216B1/ko not_active Expired - Lifetime
-
2017
- 2017-07-28 LT LTPA2017024 patent/LTC1849470I2/lt unknown
- 2017-08-01 HU HUS1700032C patent/HUS1700032I1/hu unknown
- 2017-08-03 BE BE2017C028C patent/BE2017C028I2/fr unknown
- 2017-08-08 NL NL300889C patent/NL300889I2/nl unknown
- 2017-08-08 FR FR17C1028C patent/FR17C1028I2/fr active Active
- 2017-09-06 FI FIEP06712292.9T patent/FI1849470T4/fi active
- 2017-09-07 CY CY2017029C patent/CY2017029I2/el unknown
- 2017-09-07 CY CY20171100947T patent/CY1119393T1/el unknown
- 2017-09-29 LU LU00036C patent/LUC00036I2/fr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1849470T3 (da) | Anticancerlægemiddel indeholdende alpha, alpha, alpha-trifluorthymidin og thymidinphosphorylaseinhibitor | |
| USRE46284E1 (en) | Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor | |
| JP2025013684A (ja) | 重度腎機能障害を有する癌患者に対する治療方法 | |
| KR20090025247A (ko) | 방사선 치료 증강제 | |
| MXPA04006822A (es) | Combinaciones que comprenden epotilonas y anti-metabolitos. | |
| ES2644237T3 (es) | Tratamiento de neurotoxicidad asociada a combinaciones de 5-FU o sus profármacos e inhibidores de DPD | |
| EP2268287B1 (en) | Dosage regimens of an antitumor agent comprising deoxycytidine derivative | |
| TWI401085B (zh) | Contains cytosine derivatives for continuous intravenous administration with anti-tumor agents |